Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 549

1.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
2.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
3.

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.

Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.

PMID:
23791870
4.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

5.

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.

Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG.

Antiviral Res. 2009 Jul;83(1):90-3. doi: 10.1016/j.antiviral.2009.03.003. Epub 2009 Mar 24.

PMID:
19501261
6.

Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.

Baek YH, Song MS, Lee EY, Kim YI, Kim EH, Park SJ, Park KJ, Kwon HI, Pascua PN, Lim GJ, Kim S, Yoon SW, Kim MH, Webby RJ, Choi YK.

J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.

7.

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

Baz M, Abed Y, Boivin G.

Antiviral Res. 2007 May;74(2):159-62. Epub 2006 Nov 20.

PMID:
17137644
8.

In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.

McKimm-Breschkin JL, Rootes C, Mohr PG, Barrett S, Streltsov VA.

J Antimicrob Chemother. 2012 Aug;67(8):1874-83. doi: 10.1093/jac/dks150. Epub 2012 May 4.

PMID:
22563014
9.

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV.

Antiviral Res. 2012 Mar;93(3):381-6. doi: 10.1016/j.antiviral.2012.01.006. Epub 2012 Feb 7.

PMID:
22330888
11.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

12.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.

13.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

14.

Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Pizzorno A, Bouhy X, Abed Y, Boivin G.

J Infect Dis. 2011 Jan 1;203(1):25-31. doi: 10.1093/infdis/jiq010.

15.

Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.

Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, Valette M, Lina B, Morfin F, Ferraris O.

J Clin Virol. 2008 Jan;41(1):25-8. Epub 2007 Dec 4.

PMID:
18055253
16.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

17.

Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.

Duwe SC, Wedde M, Birkner P, Schweiger B.

Antiviral Res. 2011 Jan;89(1):115-8. doi: 10.1016/j.antiviral.2010.11.001. Epub 2010 Nov 9.

PMID:
21070812
18.

Rapid discrimination of oseltamivir-resistant 275Y and -susceptible 275H substitutions in the neuraminidase gene of pandemic influenza A/H1N1 2009 virus by duplex one-step RT-PCR assay.

Nakauchi M, Ujike M, Obuchi M, Takashita E, Takayama I, Ejima M, Oba K, Konomi N, Odagiri T, Tashiro M, Kageyama T; influenza virus surveillance group of Japan.

J Med Virol. 2011 Jul;83(7):1121-7. doi: 10.1002/jmv.22101. Erratum in: J Med Virol. 2011 Aug;83(8):1491. multiple investigator names added.

PMID:
21567417
19.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

20.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Correia V, Santos LA, Gíria M, Almeida-Santos MM, Rebelo-de-Andrade H.

J Med Virol. 2015 Jan;87(1):45-56. doi: 10.1002/jmv.23986. Epub 2014 Jul 21.

PMID:
25042157

Supplemental Content

Support Center